Literature DB >> 14986200

Abnormal serotonin reuptake in an overtrained, insomnic and depressed team athlete.

A L T Uusitalo1, M Valkonen-Korhonen, P Helenius, E Vanninen, K A Bergström, J T Kuikka.   

Abstract

The purpose of this report is to study serotonin reuptake of the brain in a severely overtrained athlete by using single-photon emission computed tomography (SPECT). A 26-year-old team athlete increased his training volume (by 200 %) and intensity markedly in a new high-level team. After two months, he started to feel continuous fatigue. He had tinnitus in his left ear, he felt disturbing palpitation and had pollacisuria. After four months, he started to suffer from insomnia. He still continued to play for another three months, after which he was unable to play. He could only sleep for 3 to 4 hours per night. Only minor abnormalities could be found in extensive physical and laboratory examinations. The athlete had a severe overtraining state. In the brain SPECT scans, using the specific radioligand for serotonin transporter imaging ( (123)I labelled 2beta-carbomethoxy-3beta-[4-iodophenyl]-nortropane), low activity areas were detected in the midbrain, anterior gingulus, and left frontal and temporo-occipital lobes. In a psychiatric examination, the patient was found to have signs of major depression, which he hardly recognized himself. We conclude, that that the severe overtraining state could have been related to decreased serotonin reuptake in the brain and signs of major depression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986200     DOI: 10.1055/s-2004-819952

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  9 in total

Review 1.  Dietary fat and sports nutrition: a primer.

Authors:  Lonnie M Lowery
Journal:  J Sports Sci Med       Date:  2004-09-01       Impact factor: 2.988

2.  Psychomotor speed: possibly a new marker for overtraining syndrome.

Authors:  Esther Nederhof; Koen A P M Lemmink; Chris Visscher; Romain Meeusen; Theo Mulder
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

3.  Low brain serotonin transporter binding in major depressive disorder.

Authors:  Andrew B Newberg; Jay D Amsterdam; Nancy Wintering; Justine Shults
Journal:  Psychiatry Res       Date:  2012-06-12       Impact factor: 3.222

4.  Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.

Authors:  Matthew S Milak; Ramin V Parsey; Leilani Lee; Maria A Oquendo; Doreen M Olvet; Francoise Eipper; Kevin Malone; J John Mann
Journal:  Psychiatry Res       Date:  2009-05-14       Impact factor: 3.222

5.  Change over time in brain serotonin transporter binding in major depression: effects of therapy measured with [(123) I]-ADAM SPECT.

Authors:  Jay D Amsterdam; Andrew B Newberg; Cory F Newman; Justine Shults; Nancy Wintering; Irene Soeller
Journal:  J Neuroimaging       Date:  2013-06-10       Impact factor: 2.486

6.  Effects of Occupational and Leisure-Time Physical Activities on Insomnia in Korean Firefighters.

Authors:  Myeongseob Lim; Kyoung Sook Jeong; Sung-Soo Oh; Sang-Baek Koh; Sei-Jin Chang; Yeon-Soon Ahn
Journal:  Int J Environ Res Public Health       Date:  2020-07-27       Impact factor: 3.390

7.  The Athlete's Paradox: Adaptable Depression.

Authors:  Weronika Jasmina Forys; Tracey Tokuhama-Espinosa
Journal:  Sports (Basel)       Date:  2022-06-30

Review 8.  Diagnosing Overtraining Syndrome: A Scoping Review.

Authors:  Justin Carrard; Anne-Catherine Rigort; Christian Appenzeller-Herzog; Flora Colledge; Karsten Königstein; Timo Hinrichs; Arno Schmidt-Trucksäss
Journal:  Sports Health       Date:  2021-09-09       Impact factor: 4.355

9.  Association between the transcriptional levels of Htr-1a and tryptophan hydroxylase-1 in the hippocampus and the antifatigue effects of leucine on rats with postoperative fatigue.

Authors:  Tiantian Wu; Jing Chen; Jiang Zhu; Zhen Yu
Journal:  Exp Ther Med       Date:  2014-09-17       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.